Acer Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Acer Therapeutics's estimated annual revenue is currently $5M per year.
- Acer Therapeutics received $11.0M in venture funding in December 2017.
- Acer Therapeutics's estimated revenue per employee is $111,667
- Acer Therapeutics's total funding is $25.9M.
- Acer Therapeutics has 45 Employees.
- Acer Therapeutics grew their employee count by 61% last year.
Acer Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Acer Therapeutics?
Acer Therapeutics Inc. (Nasdaq: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need. Founded in 2013, Acer completed its Initial Public Offering in 2017, has raised $87M to date, and has rapidly built a diverse portfolio of product candidates. Our pipeline includes three clinical-stage candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of various neuroendocrine disorders. On December 26, 2018 the U.S. Food and Drug Administration (FDA) accepted for review Acer's New Drug Application (NDA) for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed COL3A1 mutation. The FDA also granted a priority review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2019. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Acer's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Acer has a strong company culture and is committed to creating and maintaining an environment that values individual rights, hard work, fosters creativity, and promotes success. The Company is growing rapidly and is fueled by the talent and expertise of our employees, driven by the commitment to treating patients with critical unmet medical needs.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Acer Therapeutics News
On average, equities research analysts anticipate that Acer Therapeutics will post -2.05 earnings per share for the current fiscal year. Hedge...
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting.
NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition...
Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND - October 7, 2021 - Acer Therapeutics Inc. (Nasdaq: ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holdi ...
EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Patent Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation 07-Oct-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsibl ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Acer Therapeutics Funding
|2016-05-11||$8.2M||B||TVM Life Science Venture VII||Article|
|2017-12-18||$11.0M||Undisclosed||William Blair & Company, L.L.C.||Article|